The FDA has issued a complete response letter for rivoceranib plus camrelizumab as a first-line treatment for unresectable ...

For patients with chronic liver disease, statin use is associated with reduced risk for hepatocellular carcinoma and hepatic decompensation.

1 Dept of Clinical Medicine, Nephrology and Health Sciences, University of Parma, Parma, Italy 2 Division of Occupational and Environmental Medicine; Department of Molecular and Clinical Medicine, ...